PRINCETON, N.J., Sept. 24 /PRNewswire-FirstCall/ -- Novo Nordisk, a world leader in diabetes care, announced that effective today, the company is listed in the Dow Jones Sustainability World Index (DJSI World) as best-in-class in the healthcare industry -- one of 18 global supersectors analyzed.
The latest global analysis of corporate sustainability leadership was based on a thorough analysis of companies' economic, environmental and social performance, assessing issues including corporate governance, risk management, branding, climate change, supply chain standards and labor practices.
The report concludes "Novo Nordisk is the leading company in terms of sustainability in the pharmaceutical industry. Sustainability is an integral part of its corporate strategy and business organization."
The report continues, "Novo Nordisk is particularly strong in the social dimension where it achieved the industry top ratings in human capital development, corporate citizenship/philanthropy, and social reporting." The company's responsible sourcing, environmental management, bioethics and climate strategy also achieve high scores.
"This honor provides us further encouragement for operating our business according to our Triple Bottom Line philosophy -- a company that can be economically vital, as well as socially and environmentally responsible," said Martin Sorters, president, Novo Nordisk in the United States.
"Our passion for changing diabetes is supported by an understanding that sustainability in business is not just possible but necessary. By putting the patient at the center of all we do -- from providing the best therapies to patients and advocating our employees' volunteerism with patient groups and at diabetes camps to our environmental stewardship through water conservation efforts and our climate change strategy -- we strive to be successful and responsible."
The indexes, which currently comprise USD$5.6 billion assets under management, are used as a tool by asset managers in 15 countries to guide their investment decisions.
Novo Nordisk has been a component of the Dow Jones Sustainability Indexes every year since the launch in 1999.
About Novo Nordisk
Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
Sean Clements Christian Qvist Frandsen
Tel: 609 514 8316 Tel: 609 919 7937
|SOURCE Novo Nordisk|
Copyright©2007 PR Newswire.
All rights reserved